Suven Life Sciences vs Peers
- Market cap
- ₹8,098 crore
- P/E
- 22.5
- P/B
- 13.69
- ROE
- -78.8%
- Dividend yield
- 1.20%
Suven Life Sciences ranks 3rd by market capitalisation among 4 Healthcare Research, Analytics & Technology companies tracked by ATS. Its largest peers are Indegene, Syngene International and Bilcare. Its P/E of 22.5 compares with a peer median of 36.4.
Suven Life Sciences vs Healthcare Research, Analytics & Technology peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Indegene | 606.00 | +1.63% | 14,576 | 36.4 | 4.64 | 13.9% | +12.5% |
| Syngene International | 360.10 | -0.85% | 14,468 | 65.5 | 2.99 | 6.6% | +12.5% |
| Suven Life Sciences | 307.05 | -0.68% | 8,098 | 22.5 | 13.69 | -78.8% | — |
| Bilcare | 94.75 | +1.99% | 223 | 28.8 | 1.13 | 0.8% | +12.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 7 October 2026. How this data is compiled.
Suven Life Sciences peer comparison — frequently asked questions
Who are Suven Life Sciences' competitors?
Suven Life Sciences' listed peers in Healthcare Research, Analytics & Technology include Indegene, Syngene International and Bilcare, ranked here by market capitalisation.
How does Suven Life Sciences' P/E compare with its peers?
Suven Life Sciences trades at a P/E of 22.5, against a median of 36.4 across the 3 Healthcare Research, Analytics & Technology peers shown.
Which is the largest company among Suven Life Sciences' peers?
By market capitalisation, the largest company in the group is Indegene at ₹14,576 crore, against ₹8,098 crore for Suven Life Sciences.
Same Data For Peers
Trade Suven Life Sciences With ATS
Track SUVEN live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.